Pharmacokinetics Of Jaktinib In Subjects With Hepatic Impairment And Normal Hepatic Function

  • participants needed
  • sponsor
    Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Updated on 16 August 2022
body mass index
liver disease
hepatic impairment
Accepts healthy volunteers


This multi-center, open-label, parallel-controlled, single-dose Phase 1 study is being conducted to directly characterize the pharmacokinetic (PK) profiles and safety of Jaktinib following administration of a single oral dose in subjects with varying degrees of hepatic impairment compared to healthy matched control subjects with normal hepatic function(matched by age, weight, and sex).

Condition Liver Disorders, Hepatic Failure, Hepatic Insufficiency, LIVER DISEASE, Liver Disease, Liver Failure, Healthy Subjects
Treatment Jaktinib hydrochloride tablets
Clinical Study IdentifierNCT04993404
SponsorSuzhou Zelgen Biopharmaceuticals Co.,Ltd
Last Modified on16 August 2022

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note